Trial · NCT02088541
Participant flow25
How many started, completed or left each group, period by period.
1 to 20 of 25
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | 71 | |
| Overall Study | STARTED | Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2) | 27 | |
| Overall Study | STARTED | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | 117 | |
| Overall Study | STARTED | Physician's Choice 1 (PV <5) | 44 | |
| Overall Study | STARTED | Physician's Choice 2 (PV >=5) | 58 | |
| Overall Study | Safety Population | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | 71 | |
| Overall Study | Safety Population | Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2) | 27 | |
| Overall Study | Safety Population | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | 115 | |
| Overall Study | Safety Population | Physician's Choice 1 (PV <5) | 39 | |
| Overall Study | Safety Population | Physician's Choice 2 (PV >=5) | 45 | |
| Overall Study | Intent-to-treat (ITT) Population | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | 0 | |
| Overall Study | Intent-to-treat (ITT) Population | Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2) | 0 | |
| Overall Study | Intent-to-treat (ITT) Population | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | 118 | |
| Overall Study | Intent-to-treat (ITT) Population | Physician's Choice 1 (PV <5) | 0 | |
| Overall Study | Intent-to-treat (ITT) Population | Physician's Choice 2 (PV >=5) | 57 | |
| Overall Study | COMPLETED | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | 0 | |
| Overall Study | COMPLETED | Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2) | 0 | |
| Overall Study | COMPLETED | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | 0 | |
| Overall Study | COMPLETED | Physician's Choice 1 (PV <5) | 0 | |
| Overall Study | COMPLETED | Physician's Choice 2 (PV >=5) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02088541/flow